Gilead Q1 rev $7.0B (+4% YoY); raises FY rev guidance but slashes EPS guidance due to $11.5B charges

GILEAD SCIENCES, INC.

2026-Q1 EPS reported $1.61 revenue$6,960,000,000

Product sales ex-Veklury $6.8B (+8% YoY); HIV sales $5.0B (+10%); Biktarvy $3.4B (+7%).
GAAP diluted EPS $1.61 (vs $1.04); non-GAAP $2.03 (vs $1.81) — both up YoY.
Full-year product sales guidance raised to $30.0-30.4B; GAAP EPS guidance cut to $(3.25)-(2.85) from $6.75-7.15.
EPS guidance reduction driven by anticipated $11.5B IPR&D charges for Arcellx, Ouro and Tubulis acquisitions.
Cell Therapy sales down 12% to $407M; Trodelvy up 37% to $402M; Veklury down 52% to $144M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

GILEAD SCIENCES, INC. reported first quarter 2026 results: revenue $7.0 billion, EPS $1.61. Guidance raised.

Period: first quarter 2026
Revenue: $7.0 billion
EPS: $1.61
Guidance: raised
Result: reported results

Exact text from the filing

in 2026, Gilead is well-positioned for sustained growth in the near and long term.” First Quarter 2026 Financial Results • Total first quarter 2026 revenues increased 4% to $7.0 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy), and Livdelzi® (seladelpar), partially offset by

View on SEC.gov

Browse all earnings releases →

GILEAD SCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000882095-26-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.